Authors: Jan Krhut 1,2; Kateřina Ryšánková 1,2; Roman Zachoval 3 Authors‘ workplace: Urologická klinika FN Ostrava 1; Katedra chirurgických oborů, LF OU Ostrava 2; Urologická klinika 3 LF UK a FTN Praha 3 Published in: Ces Urol 2024; 28(3): 133-140 Category: Review articles doi: https://doi.org/10.48095/cccu2024022
Administration of anticholinergics represents the mainstay of overactive bladder therapy Their efficacy has been proven in a number of large randomized tri als Recently, much attention has been paid to the ad verse effects of anticholinergics used in the treatment of overactive bladder on the central nervous system Current literature evidence shows a low but real risk of cognitive impairment and the development of dementia with long‑term use of anticholinergics, particularly oxybutynin and tolterodine Before start ing anticholinergic therapy, the benefits and potential risk should be carefully considered for each individual patient Particular caution is required in patients with pre‑existing cognitive impairment If anticholinergic treatment fails or side effects occur, alternative treat ment options should be considered early
Overactive bladder, anticholinergics, muscarinic receptors, cognitive impairment, dementia
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
